To the Editor We read with great interest the Brief Report by Pinato et al1 regarding the association of prior antibiotic (pATB) treatment with survival and response to immune checkpoint inhibitor (ICI) therapy in patients with cancer. The research included 196 patients who were treated with ICI therapy, and results indicated that ATB treatment administered within 30 days prior to ICI therapy was associated with reduced treatment response to ICI therapy and worse overall survival. This study focused on an important issue in clinical practice, but several points need clarification.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Yang Z, Wei S, Liu L. Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncol. Published online February 20, 2020. doi:10.1001/jamaoncol.2019.6865
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: